References
- Allen TM; Moase EH. Therapeutic opportunities for tar-geted liposomal drug delivery. Adv Drug Deliv Rev 1996; 21: 117–133.
- Maruyama K, Ishida O, Takizawa T, Moribe K. Possibility of active targeting to tumor tissues with liposomes. Adv Drug Deliv Rev 1999; 40: 89–102.
- Mamot C, Drummond DC, Hong K, Kirpotin DB, Park JW. Liposome-based approaches to overcome anticancer drug resistance. Drug Resist Updates 2003; 6: 271–279.
- Drummond DC, Meyer O, Hong K, Kirpotin DB, Papahadjopoulos D. Optimizing liposomes for delivery of chemotherapeutic agents to solid tumors. Pharmacol Rev 1999; 51: 691–743.
- Working PK, Dayan AD. Pharmacological-toxicological expert report: CAELYX (Stealth® liposomal doxorubicin HCl) (Foreword). Hum Exp Toxicol 1996; 15: 751–785.
- Gabizon A, Catane R, Uziely B, Kaufman B, Safra T. Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethyl-ene-glycol coated liposomes. Cancer Res 1994; 54: 987–992.
- Northfelt DW, Martin FJ, Working P, et al. Doxorubicin encapsulated in liposomes containing surface-bound polyethyl-ene glycol: Pharmacokinetics, tumor localization, and safety in patients with AIDS-related Kaposi's sarcoma. J Clin Pharmacol 1996; 36: 55–63.
- Batist G, Ramakrishnan G, Sekhar Rao C, et al. Reduced cardiotoxicity and preserved antitumor efficacy of liposome-encapsulated doxorubicin and cyclophosphamide compared with conventional doxorubicin and cyclophos-phamide in a randomized, multicenter trial of metastatic breast cancer. J Clin Oncol 2001; 19: 1444–1454.
- Harris L, Batist G, Belt R et al. Liposome-encapsulated doxorubicin compared with conventional doxorubicin in a ran-domized multicenter trial as first-line therapy of metastatic breast carcinoma. Cancer 2002; 94: 25–36.
- Sharpe M, Easthope SE, Keating GM, Lamb HM. Polyethylene glycol-liposomal doxorubicin: a review of its use in the management of solid and haematological malignancies and AIDS-related Kaposi's sarcoma. Drugs 2002; 62: 2089–126.